22994-85-0|苄硝唑|Benznidazol|MFCD00243089-范德生物科技公司

苄硝唑

NMR下载 COA and HPLC MSDS下载
names：
Benznidazol
CAS号：
22994-85-0
MDL Number： MFCD00243089
MF(分子式)： C12H12N4O3 MW(分子量)： 260.25
EINECS: Reaxys Number:
Pubchem ID:31593 Brand:BIOFOUNT

苄硝唑(22994-85-0,Benznidazol)是硝基咪唑衍生物，通过干扰寄生虫蛋白质的生物合成，影响细胞因子的产生并刺激宿主的吞噬作用而具有抗原生动物活性。苄硝唑是一种单羧酸酰胺，其通过将（2-硝基咪唑-1-基）乙酸的羧基与苄胺的芳族氨基缩合而获得。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000814-100mg	100mg	99.6%	¥ 2160.00	¥ 2160.00		2-3天	- +	¥ 0.00
YZM000814-25mg	25mg	99.6%	¥ 836.00	¥ 836.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	苄硝唑(22994-85-0,Benznidazol);苄哒唑
英文别名	Benznidazol(22994-85-0);Radanil;Benzonidazole
CAS号	22994-85-0
SMILES	O=C(NCC1=CC=CC=C1)CN2C=CN=C2[N+]([O-])=O
Inchi	InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)
InchiKey	CULUWZNBISUWAS-UHFFFAOYSA-N
分子式 Formula	C12H12N4O3
分子量 Molecular Weight	260.25
闪点 FP	No data available
熔点 Melting point	188-190°C
沸点 Boiling point	No data available
Polarizability极化度	27.5±0.5 10-24cm3
密度 Density	1.4±0.1 g/cm3
蒸汽压 Vapor Pressure	No data available
溶解度Solubility	生物体外In Vitro:DMSO溶解度160 mg/mL(614.79 mM;Need ultrasonic)
性状	灰白色至浅黄色固体粉末
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

苄硝唑(22994-85-0,Benznidazol) 实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Benznidazol(22994-85-0) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:苄硝唑(22994-85-0,Benznidazol),苄硝唑试剂,苄硝唑的活性,苄硝唑的抑制剂,苄硝唑的纯度,苄硝唑的图谱,苄硝唑的生产,苄硝唑的含量,苄硝唑的杂质,苄硝唑的盐酸盐,苄硝唑的厂家,苄硝唑的合成,苄硝唑的MSDS,苄硝唑的注意事项

产品说明	苄硝唑(22994-85-0,Benznidazol)是硝基杂环化合物。苄硝唑表现出三种多态形式。
Introduction	Benznidazol(22994-85-0,苄硝唑) is a nitro heterocyclic compound. Benznidazole exhibits three polymorphic forms.
Application1	Benznidazole is associated with serum enzyme elevations during therapy in up to 10% of patients but has not linked to cases of clinically apparent acute liver injury.
Application2	Benznidazole is an orally available, broad spectrum antimicrobial agent used in the treatment of Chagas disease.
Application3

Benznidazol(22994-85-0,苄硝唑) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms. It may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

象形图
信号警告	Warning
GHS危险说明	Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H315 (97.44%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (97.44%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (97.44%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范说明代码	P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Cucurbit[7]uril as a possible nanocarrier for the antichagasic benznidazole: a computational approach(Journal of Inclusion Phenomena and Macrocyclic Chemistry,2020)

Study of benznidazole–cyclodextrin inclusion complexes, cytotoxicity and trypanocidal activity(Journal of Inclusion Phenomena and Macrocyclic Chemistry,2011)

Designing and monitoring microstructural properties of oligosaccharide/co-solvent ternary complex particles to improve benznidazole dissolution

Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice

Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy

Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole
Abstract:Chagas disease is an endemic infection in Latin America with a high health impact. Caused by the parasite Trypanosoma cruzi, it has expanded to non-endemic regions such as North America and European countries via immigration of infected people. This infectious disease has been rising in the ranking of international health priorities due to the growing migration flows from endemic to non-endemic areas. Benznidazole (BZN), a nitroheterocyclic drug, is one of the two trypanocidal drugs currently in clinical use, associated with significant adverse drug reactions (ADRs). Mammalian metabolism of BNZ has been poorly studied, including the potential role of metabolites on both toxicity and anti-parasitic activity. High-resolution UPLC/MS/MS was used to analyze three plasma samples obtained from pediatric patients under BNZ treatment in steady state. Spectroscopic and structural criteria were applied to identify BNZ and accompanying substances from chromatographic signals. From all detected species, two can be undoubtedly associated with the BNZ and N-benzylacetamide molecules, the second one being a fragment of the parent drug (BZN). From the obtained results, two hypotheses could be formulated. The first one is to relate the presence of N-benzyl acetamide with the hepatic metabolism of BNZ. The second hypothesis has to do with the possible trypanocidal activity of this metabolite, as well as its role in the development of side effects, associated with the pharmacotherapy. Complementary studies should be carried out to determine the possible association of this metabolite with the BNZ treatment stages, patient’s clinical features, ADRs, and trypanocidal effectiveness.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开